Iovance Biotherapeutics, INC DEF 14A proxy statements

Iovance Biotherapeutics announces its 2026 Annual Meeting of Stockholders to be held virtually on June 10, 2026, featuring proposals for director elections, executive compensation, and an increase in authorized common stock.

Iovance Biotherapeutics announces its 2025 Annual Meeting of Stockholders, urging investors to vote on key proposals including director elections, executive compensation, auditor ratification, and equity incentive plan amendments.

Iovance Biotherapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 10, 2025, including proposals for director elections and amendments to equity incentive plans.

Iovance Biotherapeutics issues a supplement to its proxy statement to clarify voting standards and the treatment of abstentions and broker non-votes for Proposals 4 and 5 at the upcoming annual meeting.

Iovance Biotherapeutics is holding its annual shareholder meeting on June 11, 2024, to vote on the election of directors, executive compensation, ratification of the accounting firm, and amendments to equity incentive plans.

Iovance Biotherapeutics is asking stockholders to approve amendments to its 2018 Equity Incentive Plan and 2020 Employee Stock Purchase Plan at the upcoming annual meeting on June 11, 2024.